US › Healthcare

Dyadic International Inc (DYAI)

US · Healthcare · Biotechnology

$0.42+5.93%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$961,138

Revenue YoY

+107.4%

Net profit

$-2.1M

EPS

$-0.06

EPS estimate

$-0.03

Net margin

-221.0%

EPS came in at -0.06 against a street estimate of -0.03 — a miss of 100.0%.

Key statistics

Market cap

$19.4M

Forward P/E

15.8

P/B

21.01

Book value

$-0.07

EPS (TTM)

$-0.21

52-week high

$1.60

52-week low

$0.46

50-day MA

$0.90

200-day MA

$0.85

Beta

0.96

Analyst view

Analysts rate Dyadic International Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.50.

Shareholding

Insiders

22.90%

Institutions

12.32%

Largest institutional holders

Fund	Stake
Apis Capital Advisors, LLC	3.17%
Vanguard Capital Management, LLC	2.32%
Chapin Davis Inc	2.22%
BB&T Corp.	0.81%
Geode Capital Management, LLC	0.78%
BlackRock Inc	0.69%
Vanguard Fiduciary Trust Co	0.35%
Marathon Capital Management LLC	0.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dyadic International Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.